Dr Reddy’s expands biosimilar portfolio with Alvotech tie up

Alvotech, a global biotech company specialising in the development and manufacture of biosimilar medicines, and Dr Reddy’s Laboratories SA, a wholly-owned subsidiary of Dr Reddy’s Laboratories Ltd, on Tuesday announced that the companies have entered into a license and supply agreement for the commercialisation of AVT03, Alvotech’s biosimilar candidate to Prolia, and Xgeva (denosumab).

Under the collaboration, Alvotech will be responsible for development and manufacturing of the product, while Dr Reddy’s will be responsible for registration and commercialisation of the product in the applicable markets. The license and supply agreement includes an upfront payment to Alvotech, with additional payments upon certain regulatory and commercialisation milestones as well as sales-based payments. Dr Reddy’s commercialisation rights are exclusive for the US, and semi-exclusive for Europe and the UK, an official release said.

Prolia and Xgeva are indicated for the treatment of various diseases including osteoporosis in post-menopausal women and prevention of skeletal-related events in adults with advanced malignancies.

Erez Israeli, Chief Executive Officer, Dr Reddy’s, said: “We are pleased to collaborate with Alvotech to make this denosumab biosimilar available to patients in the US, Europe and UK. Over the years, we have created a portfolio of biosimilar products, which are marketed in several emerging markets. This strategic collaboration augments our growing portfolio of biosimilar offerings, and progresses our biosimilar journey further into the highly regulated markets.”